Peptide (e.g., Protein, Etc.) Containing Doai Patents (Class 514/1.1)
  • Patent number: 11209434
    Abstract: The present invention is directed toward novel methods to identify as well as to treat a subject having an inflammatory disease resistant to corticosteroids.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: December 28, 2021
    Assignee: National Jewish Health
    Inventors: Donald Y. M. Leung, Elena Goleva, Lingbo Li
  • Patent number: 11202819
    Abstract: The disclosure relates to the use of variants of C-type natriuretic peptide (CNP) to treat osteoarthritis, to ameliorate one or more symptoms of osteoarthritis, and to treat disorders having an osteoarthritis component.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: December 21, 2021
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Charles A. O'Neill, Todd M. Oppeneer, Jason K. Pinkstaff
  • Patent number: 11197853
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: December 14, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Patent number: 11185538
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: November 30, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Patent number: 11185577
    Abstract: Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Hideho Okada, Yafei Hou
  • Patent number: 11162500
    Abstract: A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: November 2, 2021
    Assignee: Amgen Inc.
    Inventors: Derek Maclean, Qun Yin
  • Patent number: 11160843
    Abstract: The present invention relates to the discovery that co-administration of both oxytocin (OT) and at least one opioid antagonist can increase social function in a subject. In certain embodiments, the co-administration can be used to treat one or more social dysfunction disorders in a subject, including, but not limited to autism, schizophrenia, anxiety disorders and post-traumatic stress disorder (PTSD). In other embodiments, the OT and the opioid antagonist can be co-administered to a subject as an aerosolized pharmaceutical composition.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 2, 2021
    Assignee: Yale University
    Inventors: Wohn Chui Chang, Olga Dal Monte, Matthew Piva
  • Patent number: 11147781
    Abstract: Disclosed herein are methods and compositions for alleviating side effects of statin administration, such as myopathic or myalgic side effects, short-term memory loss, abnormal liver function, glucose intolerance, hyperglycemia, increased risk for diabetes, or cumulative trauma disorder, comprising administration of ?-hydroxy ?-methylbutyrate (HMB) to an individual taking a statin. Also disclosed are methods and compositions for alleviating acute rhabdomyolysis comprising administration of HMB. The disclosure further provides uses of HMB in combination with a statin to alleviate side effects of statin administration.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: October 19, 2021
    Inventor: Roland W. Winterfield
  • Patent number: 11142577
    Abstract: Wnt signaling agonist compositions and methods for their use are provided. Wnt signaling agonists of the invention comprise a frizzled binding moiety, which is fused or conjugated to an LRP5 or LRP6 binding moiety.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 12, 2021
    Assignees: The Board of Trustees of the Leland Stanford Junior University, University of Washington
    Inventors: Kenan Christopher Garcia, David Baker, Claudia Yvonne Janda, Luke Dang, James Daniel Moody
  • Patent number: 11142559
    Abstract: The present invention relates to a glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof, and in particular, for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: October 12, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung
  • Patent number: 11141459
    Abstract: The present disclosure relates to suppression of cellular transformation and dysplasia by topical application of Lefty. In particular, the present disclosure provides compositions and methods for topically applying Lefty to treat and prevent cancers.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 12, 2021
    Assignee: GRANT LABS, INC.
    Inventor: Charles E. Craft
  • Patent number: 11135267
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 5, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 11129404
    Abstract: Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: September 28, 2021
    Assignee: ABBOTT LABORATORIES
    Inventors: Tapas Das, Mustafa Vurma, Chron-Si Lai, Paul Johns
  • Patent number: 11130812
    Abstract: The present invention discloses anti-PD-L/PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor/cancer.
    Type: Grant
    Filed: August 29, 2015
    Date of Patent: September 28, 2021
    Assignee: BIRDIE BIOPHARMACEUTICALS, INC.
    Inventors: Lixin Li, Walter Lau
  • Patent number: 11123437
    Abstract: The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.
    Type: Grant
    Filed: January 26, 2020
    Date of Patent: September 21, 2021
    Assignee: Mainline Biosciences, Inc.
    Inventors: Junge Zhang, Liang Zeng Yan
  • Patent number: 11117947
    Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K27, and the second K residue is designated KT; which derivative comprises two albumin binding moieties attached to K27 and KT, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC—(CH2)x—CO— and HOOC—C6H4—O—(CH2)y—CO—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —NH—(CH2)2—(O—(CH2)2)k—O—(CH2)n—CO—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or este
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: September 14, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Jane Spetzler, Thomas Kruse, Lars Linderoth, Jacob Kofoed
  • Patent number: 11116827
    Abstract: In certain embodiments, methods and compositions are provided for generating immune responses against tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof. In particular embodiments, there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor antigens such as antigens or epitopes of HER1, HER2/neu, HER3, HER4, or any combination thereof, that allow for vaccinations in individuals with preexisting immunity to adenovirus.
    Type: Grant
    Filed: June 2, 2018
    Date of Patent: September 14, 2021
    Assignee: Etubics Corporation
    Inventors: Frank R. Jones, Joseph Balint, Elizabeth Gabitzsch
  • Patent number: 11110079
    Abstract: Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: September 7, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Gregory Riggins, Renyuan Bai, Verena Staedtke, Avadhut D. Joshi, Tara Williamson
  • Patent number: 11098112
    Abstract: The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: August 24, 2021
    Assignee: Regeneron Pharmnaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal
  • Patent number: 11096968
    Abstract: The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate thereof: (I).
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 24, 2021
    Assignee: Protokinetix Inc.
    Inventor: Lachlan Grant Young
  • Patent number: 11090354
    Abstract: The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders. The compositions include components for forming luminal barriers within the gastrointestinal tract of a subject where the barrier is created in-situ via interaction of resident mucin with the mucin-interacting agent.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: August 17, 2021
    Assignee: The Johns Hopkins University
    Inventors: Thomas Jozefiak, Michael Parlato, Pratik Patel, Kevin Colbert, Ashish Nimgaonkar, Pankaj Pasricha
  • Patent number: 11090292
    Abstract: The invention provides for a method of treating inappetance-induced weight loss in one or more companion animals or livestock. The method provides for administering a therapeutically effective amount of a capromorelin-containing composition to the companion animal or livestock. Optionally, one or more flavoring agents or flavor-masking agents can be added to the capromorelin-containing composition to enhance or mask the flavoring of the composition for the companion animal or livestock.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: August 17, 2021
    Assignee: Aratana Therapeutics, Inc.
    Inventors: Bill Zollers, Linda Rhodes, Ernst Heinen, Gopinath Devaraj
  • Patent number: 11085055
    Abstract: They are provided gene constructs comprising a nucleotide sequence encoding the Insulin-like growth factor 1 (IGF-1) of a mammal; and target sequences of a microRNA of a tissue where the expression of IGF-1 is wanted to be prevented, wherein the sequences (a) and (b) are operationally linked to a promoter of ubiquitous expression. Also provided are expression vectors comprising the gene construct and pharmaceutical compositions comprising them. They are useful in the treatment and/or prevention of diabetes mellitus in mammals, wherein a dysfunction and/or a loss of the beta-cells of the islets of Langerhans is present.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: August 10, 2021
    Inventors: Cristina Mallol Dominguez, Fatima Bosch Tubert, Veronica Jimenez Cenzano
  • Patent number: 11077059
    Abstract: The invention provides methods for the preparation of particles including one or more agents, e.g., therapeutic or diagnostic agents. The particles can be formed by creating droplets of a first liquid, e.g., including an agent, and removing the first liquid, e.g., through its dispersal in a second liquid and/or evaporation, to solidify the droplets. Advantageously, the process of forming the particles does not significantly alter the structure or activity of the agents and may enhance the stability of the agents. For example, the particles may be stored for long periods of time without significant loss of activity, and in some embodiments, without the need for refrigeration. These particles may be used to generate stabilized pharmaceutical compositions for storage or other logistical purposes, pharmaceutical suspensions, pharmaceutical powder formulations (e.g., inhalable powders, injectable powders), creams or other topical pastes, nutraceuticals, or cosmetics.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: August 3, 2021
    Assignee: Elektrofi, Inc.
    Inventors: Chase Spenser Coffman, Lyndon Fitzgerald Charles, Jr., Paul Brown, Daniel Benjamin Dadon, Lisa Liu, Cory Robinson, Dale Arlington Thomas, III
  • Patent number: 11078236
    Abstract: This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: August 3, 2021
    Assignee: Burke Neurological Institute
    Inventors: Rajiv R Ratan, Ishraq Alim, I, Saravanan Karuppagounder
  • Patent number: 11078263
    Abstract: FN3 domains that specifically bind Fc?RII, their conjugates and antibody fusions, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: August 3, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Brian Whitaker, Di Zhang
  • Patent number: 11077173
    Abstract: The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: August 3, 2021
    Assignee: SDG, Inc.
    Inventor: W. Blair Geho
  • Patent number: 11065305
    Abstract: A composition in the form of an injectable aqueous solution, with pH from 3.5 to 4.4, including at least human insulin A21G and at least one glucagon suppressor with prandial action. In an embodiment, the glucagon suppressor with prandial action is selected from an amylin analog or an amylin receptor agonist or a GLP-1 analog or a GLP-1 receptor agonist (GLP-1 RA). In an embodiment, the glucagon suppressor with prandial action is an amylin analog or an amylin receptor agonist. In an embodiment, the glucagon suppressor peptide with prandial action is pramlintide. Also, a method for obtaining human insulin A21G, includes at least one step of reacting human insulin A21G, B31R, B32R (insulin glargine) with rat carboxypeptidase B at an insulin/carboxypeptidase ratio from 500 to 2000, at a pH from 7.5 to 8.5 and a temperature from 20 to 30° C. for 10 to 20 hours.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: July 20, 2021
    Assignee: ADOCIA
    Inventor: You-Ping Chan
  • Patent number: 11067572
    Abstract: The methods and compositions described herein relate to the measurement of factor VIII (fVIII) levels and/or activity.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 20, 2021
    Assignees: President and Fellows of Harvard College, The U.S. Government as Represented by The Department of Veterans Affairs
    Inventors: Gary Eugene Gilbert, Jialan Shi, Valerie A. Novakovic
  • Patent number: 11059859
    Abstract: Provided a peptide of the sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys or a salt thereof for use in the treatment of inflammation, of an inflammatory disorder and/or of ion thea condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: July 13, 2021
    Assignee: JIANGYIN USUN PHARMACEUTICAL CO., LTD.
    Inventors: Bengt Ingemar Samuelsson, Ming Gu
  • Patent number: 11059885
    Abstract: The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: July 13, 2021
    Assignee: AskGene Pharma Inc.
    Inventors: Yuefeng Lu, Jian-Feng Lu
  • Patent number: 11058758
    Abstract: The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: July 13, 2021
    Assignee: National Institutes of Biomedical Innovation, Health and Nutrition
    Inventors: Ken Ishii, Etsushi Kuroda, Burcu Temizoz
  • Patent number: 11046739
    Abstract: Provided herein are polypeptides containing stabilized BH4 domains of BCL-2 family proteins that are capable of binding and/or inactivating and/or modulating BAX protein, and/or its close homologues BAK and BOK, and/or other physiological BH4 targets. Also provided are compositions containing these polypeptides and methods of treating cytotoxic diseases that include administering to a subject one of the polypeptides.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: June 29, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Michelle L. Stewart, Lauren Barclay
  • Patent number: 11039616
    Abstract: Provided herein are photodynamic compositions that can contain a natural polymer scaffold and a photosensitizer, where the photosensitizer can be covalently or non-covalently attached to the natural polymer scaffold. Also provided herein are structures and objects that can contain the photodynamic compositions. Further provided herein are methods of making and using the photodynamic compositions.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: June 22, 2021
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Reza Arman Ghiladi, Dimitris Argyropoulos, Frank Scholle
  • Patent number: 11040084
    Abstract: The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: June 22, 2021
    Assignee: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
    Inventors: Gang Qin, Jinduo Yuan, Lu Jiang, Chubing Tan, Lili Shi, Cao Lv, Leilei Chen
  • Patent number: 11034761
    Abstract: The present disclosure provides compositions and methods for reducing adiposity by inhibiting FSH/FHSR in a subject in need thereof.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: June 15, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventor: Mone Zaidi
  • Patent number: 11033603
    Abstract: The present invention provides a method for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME), which comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of beauvericin.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: June 15, 2021
    Assignee: ZIH YUAN TANG BIOTECHNOLOGY CO., LTD.
    Inventors: Shoei-Sheng Lee, Ming-Jai Su, Lung-Jr Lin, Chao-Min Hsu
  • Patent number: 11033613
    Abstract: This invention provides methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, by administering a combination of at least one WT1 peptide, or cytotoxic T cells (CTLs) against a WT1-expressing cancer, and at least one checkpoint inhibitor. The at least one WT1 peptide can be administered to the subject by administering one or more agents to the subject resulting in delivery of one or more WT1 peptides and induction of an immune response against the WT1-expressing cancer. Examples of these WT1 delivery agents include: (i) an isolated WT1 peptide, (ii) a nucleic acid encoding the at least one WT1 peptide, and (iii) an immune cell comprising or presenting the at least one WT1 peptide or nucleic acid encoding the at least one WT1 peptide.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: June 15, 2021
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventor: David Scheinberg
  • Patent number: 11026891
    Abstract: The present invention provides polymersomes comprising non-biodegradable amphiphilic block-copolymers and their enteral (e.g., oral) or topical use in the treatment of an ammonia or ammonia methylated analog-associated disease or disorder or symptom thereof (e.g., hyperammonemia or trimethylaminuria). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid. It also provides a method of making the polymersome comprising mixing the copolymer-containing organic solvent phase with an aqueous phase containing the acid.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: June 8, 2021
    Assignee: Eth Zurich
    Inventors: Jean-Christophe Leroux, Simon Matoori, Aaron Christoph Schmidt
  • Patent number: 11021727
    Abstract: Recombinant microorganisms are disclosed that produce steviol glycosides and have altered expression of one or more endogenous transporter or transcription factor genes, or that overexpress one or more heterologous transporters, leading to increased excretions of steviol glucosides of interest.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: June 1, 2021
    Assignee: EVOLVA SA
    Inventors: Ernesto Simon, Iben Nordmark Anderson, Michael Dalgaard Mikkelsen, Jorgen Hansen, Veronique Douchin
  • Patent number: 11013873
    Abstract: The present system is directed in one embodiment to a method of administration of a therapeutic composition for treatment, prevention and/or mitigation of the frequency and/or severity of impaired awareness of hypoglycemia (IAH). The method includes administering one or more therapeutic agent(s) or composition(s) comprising insulin to the upper third of a patient's nasal cavity, thereby delivering the therapeutic composition directly to the patient's central nervous system for treatment, prevention and/or mitigation of the frequency and/or severity of IAH. In still another embodiment, the therapeutic composition comprises a non-zinc containing form of insulin.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: May 25, 2021
    Assignee: HealthPartners Institite
    Inventors: William H. Frey, II, Richard M. Bergenstal, Leah R. Bresin Hanson, Anders L. Carlson
  • Patent number: 11013403
    Abstract: Provided are methods for assessment of surface rugosity of a layer of live cells using tools that determine contact angle and contact angle hysteresis.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: May 25, 2021
    Assignees: The Regents of the University of California, Wisconsin Alumni Research Foundation
    Inventors: Christopher J. Murphy, Bernardo Yañez-Soto, Vijay Krishna Raghunathan, Nicholas L. Abbott
  • Patent number: 11000555
    Abstract: Disclosed is a compound, prepared by extracting and separating from Limax. Also disclosed is a method for extracting and separating the compound, which is simple and easy to operate. The compound has sedative and hypnotic effects, and has significant effects on physiological or psychological dependent detoxification or detoxication. It has potential application value for preparing detoxification or detoxication drugs, and provides new ideas for the further development of detoxification drugs.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: May 11, 2021
    Assignee: GUANGXI JIUFU BIOTECHNOLOGY CO., LTD
    Inventor: Jun Ruan
  • Patent number: 10995120
    Abstract: The invention encompasses components from microbial cells which are useful for antibody production, including peptides, polypeptides comprising these peptides, polynucleotides which encode these peptides or polypeptides, and antibodies directed to these peptides, polypeptides, or polynucleotides. The invention also encompasses to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further encompasses methods and compositions, especially vaccine compositions, for detecting, targeting, and inhibiting microbial cells, especially methanogen cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: May 4, 2021
    Assignee: PASTORAL GREENHOUSE GAS RESEARCH LIMITED
    Inventors: Eric Heinz Altermann, Graeme Trevor Attwood, Dong Li, William John Kelly, Zhanhao Kong, Sinead Christine Leahy
  • Patent number: 10988524
    Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-X-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(X34)d-NH2-Cter. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof. Further provided is the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition for use as a medicament.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 27, 2021
    Assignee: SANOFI
    Inventors: Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Frank Marguet, Olivier Duclos, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
  • Patent number: 10990797
    Abstract: Microscopic object characterization system (1), comprising a computer system (2, 2a, 2b), a microscope (4) with a computing unit (5) connected to the computer system, and an object characterization program (17) executable in the computer system configured to receive refractive index data representing at least a spatial distribution of measured values of refractive index (RI) or values correlated to refractive index of said microscopic object. The object characterization program is operable to execute an algorithm applying a plurality of transformations on said refractive index data. The transformations generate a distribution of two or more parameters used to characterize features of the microscopic object.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: April 27, 2021
    Assignee: NANOLIVE SA
    Inventors: Yann Cotte, Sebastien Equis, Bastian Dalla Piazza, Sorin Pop, Luca Clario, Christopher Tremblay, Pierre-Alain Cotte
  • Patent number: 10988523
    Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-Ac-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(K)d-(X35)e-(gE)f-X37-Cter; or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 27, 2021
    Assignee: SANOFI
    Inventors: Denis Brasseur, Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Frank Marguet, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
  • Patent number: 10987401
    Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 27, 2021
    Assignee: Allysta Pharmaceuticals, Inc.
    Inventor: Henry Hsu
  • Patent number: 10973920
    Abstract: A molecule comprising a saccharide bound via an O-glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group, and a saccharide bound via an O-glycosidic bond to a hydroxyl group of the toxic payload molecule is further disclosed.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: April 13, 2021
    Assignee: GLYKOS FINLAND OY
    Inventors: Jari Helin, Juhani Saarinen, Tero Satomaa, Filip S. Ekholm
  • Patent number: 10973757
    Abstract: A microneedle device for delivering therapeutic ingredients to the dermis or epidermis. The device contains biodegradable microneedles, which extend from a backing, and are sandwiched between a cap film and a film which is coextensive with the tips of the microneedles and the spaces on the backing between the microneedles.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: April 13, 2021
    Assignee: StemProtein, LLC
    Inventor: Nikolai Tankovich